Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%.
The iShares Biotechnology ETF (IBB) rose 1.8%.
In corporate news, Pfizer (PFE) secured exclusive global rights, excluding China, to biopharmaceutical firm 3SBio's cancer treatment candidate in a licensing deal worth up to $6.05 billion. Pfizer shares gained 2.1%.
The US Food and Drug Administration plans to require new clinical trials prior to approval of COVID-19 boosters for healthy Americans under the age of 65, agency leaders said Tuesday in a post published on the New England Journal of Medicine. Moderna (MRNA) shares were rising past 8%.
NeurAxis' (NRXS) shares jumped more than 64% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device to treat functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.